Abstract
Recent transcriptome studies using next-generation sequencing have detected aberrant changes in the expression of long noncoding (lnc) RNA associated with cancer. Systematic analysis of transcription factor-binding sites and the regulated transcripts revealed that many lncRNAs are widely regulated at the transcriptional level. However, the functions of these transcripts have not been fully elucidated. In this study, using prostate cancer cells, we explored androgen receptor (AR)-regulated noncoding RNAs by a global transcriptome analysis. We found that the expression of a novel lncRNA (named CTBP1-AS) in the antisense region of CTBP1 (carboxyl terminal binding protein 1) is rapidly induced by androgen treatment. CTBP1-AS is enriched in the nucleus of cancer cells and promotes androgen-dependent and castration-resistant tumor growth. We further presented the novel regulatory mechanism by which CTBP1-AS mediates epigenomic transcriptional control in the nucleus. CTBP1-AS interacts with an RNA-binding transcriptional and splicing factor, SFPQ/PSF, and repressed cell cycle regulators or AR coregulators including CTBP1. Thus, we showed that the expression of this novel lncRNA is induced by androgen treatment, and the lncRNA promotes prostate cancer growth.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
Bergerat JP, Ceraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30:145–157
Bergman LM et al (2009) CtBPs promote cell survival through the maintenance of mitotic fidelity. Mol Cell Biol 29:4539–4551
Buchanan G et al (2001) Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273–1281
Bussemakers MJ et al (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979
Cai C et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457–471
Callewaert L et al (2006) Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 66:543–553
Carninci P et al (2005) The transcriptional landscape of the mammalian genome. Science 309:1559–1563
Chamberlain NL et al (1996) Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. J Biol Chem 271:26772–26778
Chen CD et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39
Chen Z et al (2011) Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 30:2405–2419
Chinnadurai G (2007) Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 39:1593–1607
Culig Z et al (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242–251
Debes JD, Tindall DJ (2004) Mechanism of androgen-refractory prostate cancer. N Engl J Med 351:1488–1490
Dehm SM et al (2007) Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cells. Cancer Res 67:10067–10077
Derrien T et al (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22:1775–1789
Djebali S et al (2012) Landscape of transcription in human cells. Nature 489:101–108
Du Z et al (2013) Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol 20:908–913
Duff J et al (2006) Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease. Biochem Soc Trans 34:1098–1102
Ferreira LB et al (2013) PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer 12:507
Gupta RA et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076
Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9:703–719
Hayes SA et al (2001) SMAD3 represses androgen receptor-mediated transcription. Cancer Res 61:2112–2118
Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808
Heery DM et al (1997) A signature motif in transcriptional co-activatorsmediates binding to nuclear receptors. Nature 387:733–736
Hessels D, Schalken JA (2009) The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 6:255–261
Huarte M et al (2010) A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142:409–419
Jenster G et al (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396–1404
Jenster G et al (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270:7341–7346
Jia L et al (2008) Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3:e3645
Kahl P et al (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66:11341–11347
Kan Z et al (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869–873
Katayama S et al (2005) Antisense transcription in the mammalian transcriptome. Science 309:1564–1566
Kokontis JM et al (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566–1573
Kung JT, Lee JT (2013) RNA in the loop. Dev Cell 24:565–567
Lee JT (2012) Epigenetic regulation by long noncoding RNAs. Science 338:1435–1439
Lee GL et al (2011) Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 8:123–124
Leyten GH et al (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65:534–542
Lin DW et al (2013) Urinary TMPRSS2: ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the canary prostate active surveillance study. Clin Cancer Res 19:2442–2450
Locke JA et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415
Massie CE et al (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8:871–878
Mercer TR et al (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20:300–307
Metzger E et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436–439
Moran VA et al (2012) Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 40:6391–6400
Ogawa Y et al (2008) Intersection of the RNA interference and X-inactivation pathways. Science 320:1336–1341
Paris PL et al (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumor. Hum Mol Genet 13:1303–1313
Petrovics G et al (2004) Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 23:605–611
Prensner JR et al (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742–749
Prensner JR et al (2013) The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45(11):1392–1398
Prensner JR et al (2014) PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74(6):1651–1660
Ren S et al (2013) Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol 190:2278–2287
Rokhlin OW et al (2005) Androgen regulates apoptosis induced by TNFR family ligands via multiple signal pathway in LNCaP. Oncogene 24:6733–6784
Rosok O et al (2004) Systematic identification of sense–antisense transcripts in mammalian cells. Nat Biotechnol 22:104–108
Schlomn T et al (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21:1371–1378
Schmidt LJ, Tindall DJ (2011) Steroid 5 alpha-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol 125:32–38
Shang Y et al (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601–610
Shav-Tal Y, Zipori D (2002) PSF and p54(nrb)/NonO–multi-functional nuclear proteins. FEBS Lett 531:109–114
Shenk JL et al (2001) p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276:38472–38479
Shi Y et al (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735–738
Shiraki T et al (2003) Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci U S A 100:15776–15781
Song X, Sui A, Garen A (2004) Binding of mouse VL30 retrotransposon RNA to PSF protein induces genes repressed by PSF: effects on steroidogenesis and oncogenesis. Proc Natl Acad Sci U S A 101:621–626
Song K et al (2010) DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol Endocrinol 24:2019–2029
Srikantan V et al (2000) PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 97:12216–12221
Sun S et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715–2730
Takayama K et al (2007) Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 26:4453–4463
Takayama K et al (2009) Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 69:137–142
Takayama K et al (2011) Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30(5):619–630
Takayama K et al (2012) TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol 26:748–761
Takayama K et al (2013) Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 32:1665–1680
Tan PY et al (2012) Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol 32:399–414
Taplin ME et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398
Taplin ME et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673–2678
Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11–22
Tsai MC et al (2010) Long noncoding RNA as modular scaffold of histone modification complexes. Science 329(5992):689–693
Umesono K, Evans RM (1989) Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57:1139–1146
Urbanucci A et al (2012) Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31:2153–2163
Visakorpi T et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406
Waltering KK et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149
Wang Q et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380–392
Wang Q et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256
Wang D et al (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474:390–394
Wissmann M et al (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9:347–353
Yang L et al (2013) lncRNA-dependent mechanisms of androgen-receptor regulated gene activation programs. Nature 500:598–602
Yap KL et al (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a Mol. Cell 38:662–674
Yu W et al (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451:202–206
Yu J et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17:443–454
Zhou ZX et al (1995) Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208–218
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Takayama, Ki., Inoue, S. (2015). The Role of Androgen-Regulated Long Noncoding RNAs in Prostate Cancer. In: Kurokawa, R. (eds) Long Noncoding RNAs. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55576-6_11
Download citation
DOI: https://doi.org/10.1007/978-4-431-55576-6_11
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55575-9
Online ISBN: 978-4-431-55576-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)